WSQMS Homepage


Feb 9, 2016

New FDA Draft Guidance on Safety Assessment for IND Safety Reporting
The new Draft Guidance on Safety Assessment for IND Safety Reporting is open for comments to be sent to FDA

This document provides guidance to sponsors on developing a systematic approach for investigational new drug application (IND) safety reporting for human drugs and biological products developed under an IND.

This guidance is a follow-on to the guidance for industry and investigators Safety Reporting Requirements for INDs and BA/BE Studies and provides recommendations for how sponsors of INDs can identify and evaluate important safety information that must be submitted to FDA and all participating investigators under the IND safety reporting regulations.

This guidance contains recommendations on the following: (1) the composition and role of a safety assessment committee, (2) aggregate analyses for comparison of adverse event rates across treatment groups, (3) planned unblinding of safety data, (4) reporting thresholds for IND safety reporting, and (5) the development of a safety surveillance plan.

Read the pdf

EMA delays enforcement of new Clinical Trial Regulation
EMA will not enforce the new Clinical Trial Regulation as planned in May 2016 – 2017 is more likely

The December meeting of the European Medicines Agency's management board offered tidings of less than total comfort and joy to the clinical trials community. The agency's holiday message was a disappointment to those hoping for rapid progress on bringing Europe's new clinical trials rules into effect. The legislation, finalized in May last year—that is, 2014—said the new regulation would not be in force before May next year—that is, 2016. But the EMA board, which had already admitted that 2017 was a more likely date, disrupted the festive season with the news that the horizon for the clinical trial rules had shifted still further away, and is now October 2018.

The announcement has provoked some sharp reactions among those battling with the incoherencies of the EU's current rules on clinical trials—which the new regulation was designed to remedy. The agency's protestations of the need for a meticulous approach have not assuaged the impatience of development staff still laboring through the complexities of the much-criticized 2001 directive.

Read more online

Germany: New Anti-Corruption Law
Fighting Private Sector Bribery and Cross-Border Corruption

Statistics from the Federal Criminal Police Office show that the number of corruption-related offences committed in 2013 increased to 3,995. The new regulation on taking and giving bribes in commercial practice under Section 299 of the Criminal Code is intended to implement international standards in light of growing cross-border corruption. After intensely controversial hearings and some late changes, the new anti-corruption law was passed by Parliament and came into force on November 26 2015.

This will have some implication on compliance and its functions:

Read more online

EMA launches new IT System
On 1 February 2016, the Agency is launching a new IT system to answer stakeholders’ IT-related queries and services.

This new system is a web based portal which will replace the existing functional email addresses used to communicate in respect of a specific EMA supported IT system (e.g. for queries relating to Article 57, for EudraVigilance, for EudraCT and for EU CTR etc). Thus, from 1 February, functional email addresses on EMA webpages will be replaced with a link to the self-service portal, where applicable.

This portal will improve the efficiency and effectiveness of the technical support provided by allowing users to request IT services, report technical issues, track progress and obtain answers to frequently asked questions – all in one place.

Things to remember as of 1 February 2016:

To log in into this new portal, users will need to register to the new portal (a one-time, automated process), if not already registered for any of the Agency’s other systems (e.g. EudraCT).

All technical IT requests and issues in relation to EMA supported IT systems will be dealt with through this portal. Any ongoing incidents or service requests that were logged before 1 February will be handled using the existing process.

The existing support email addresses will not be monitored from 1 February. Those that send emails to any of those addresses (if, for instance, they have saved the address) will receive an automated response that will include a link to the new portal.

Stronger data protection rules for Europe
The EU adopts the data protection reform package

The European Parliament and Council have reached agreement on the data protection reform proposed by the Commission. The reform is an essential step to strengthen citizens' fundamental rights in the digital age and facilitate business by simplifying rules for companies in the Digital Single Market.

The data protection reform package includes the General Data Protection Regulation ("Regulation") and the Data Protection Directive for the police and criminal justice sector.

Read more online


You receive this newsletter, because you have subscribed to it.
If you no longer want to receive this newsletter, you can easily leave the list at this Website.You can't view the images in this e-mail? Click here to open it in your browser.

Widler & Schiemann AG - Weinberghöhe 10 B - CH 6300 Zug, Switzerland - VAT number: CHE-472.215.777 MWST - Public Limited Company according to Swiss Common Law - Managing Partner: Dr. Beat Widler, Dr. Peter Schiemann - +41 41 558 9193 - -